Real-world evidence of chemotherapy effects in advanced pancreatic ductal adenocarcinoma: prognostic significance of TP53 status in gemcitabine plus nab-paclitaxel therapy

Background: Gemcitabine plus nab-paclitaxel (GnP) and FOLFIRINOX (FFX) therapies are widely used to treat advanced pancreatic ductal adenocarcinoma (PDAC). This study aimed to identify the prognostic factors associated with these regimens, focusing on key genomic alterations in the ‘Big Four’ genes...

Full description

Saved in:

Bibliographic Details
Main Authors:	M. Sugimori, A. Hirotani, H. Yamazaki, M. Oshi, K. Kawashima, H. Tsuchiya, Y. Kanemaru, Y. Suzuki, S. Onodera, H. Miwa, A. Nozaki, K. Sugimori, C. Kunisaki, M. Kudo, M. Morimoto, S. Maeda
Format:	Article
Language:	English
Published:	Elsevier 2025-09-01
Series:	ESMO Gastrointestinal Oncology
Subjects:	genomic profiles pancreatic ductal adenocarcinoma time to progression tumour protein p53 mutations gemcitabine plus nab-paclitaxel therapy leucovorin, fluorouracil, irinotecan, and oxaliplatin therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2949819825000901
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Real-world evidence of chemotherapy effects in advanced pancreatic ductal adenocarcinoma: prognostic significance of TP53 status in gemcitabine plus nab-paclitaxel therapy

Similar Items